05:41 PM EDT, 04/10/2025 (MT Newswires) -- Shuttle Pharmaceuticals ( SHPH ) said late Thursday it filed a provisional US patent for prostate-specific membrane antigen ligand conjugates to treat prostrate cancer.

The patent, "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy," could advance diagnostic and therapeutic programs for patients with metastatic castration-resistant prostate cancer, the company said.

PSMA is expressed on the surface of cancer cells, and ligands targeting the antigen are smaller and present potential advantages for more efficient drug delivery, according to a company statement.

Shares are up nearly 10% in after-hours activity.